Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02740153
Other study ID # 7282
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 4, 2016
Est. completion date June 30, 2020

Study information

Verified date January 2021
Source Children's National Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Urea cycle disorders (UCD) are genetic disorders caused by the liver's inability to break down ammonia from proteins; ammonia then accumulates and is toxic to the brain. UCD cause brain damage and intellectual and developmental disabilities and even death. Treatment for UCD is either conservative management which involves a low-in-protein diet, drugs, and amino acid supplements or liver transplantation; each carries their own risks. This study aims to help patients to make the decision about different management alternatives by providing them with scientific information that is currently lacking. Aim 1 of this study will compare survival, neurocognitive function, and patient-reported quality of life.


Description:

Urea cycle disorders (UCD) are genetic disorders caused by the liver's inability to break down ammonia from proteins; ammonia then accumulates and is toxic to the brain. UCD cause brain damage and intellectual and developmental disabilities and even death. Treatment involves a special diet low in protein, drugs that help metabolize ammonia and amino acid supplements (conservative management). Many patients and families choose liver transplantation rather than conservative treatment; both alternatives are effective in reducing or normalizing blood ammonia. While liver transplantation eliminates the ammonia problem, conservative management does so only temporarily and in many patients, blood ammonia can rise during an infection. The long-term objective of this study is to help patients make decisions about management alternatives (conservative vs. liver transplantation) by providing them with scientific information that is currently lacking. The questions the investigators will address are: 1. What is the disease's risk of mortality and illness in the two treatment approaches? 2. What can parents expect in terms of the development of their child and his/her school performance? 3. What are the expected effects of each treatment on short-term and long-term quality of life? The investigators will use statistical methods to compare numbers or percentages of survival, illness, psychological testing for IQ, executive function, memory, behaviors, and quality of life among patients that choose conservative management and those who have chosen liver transplantation. Some of this information is already being collected by the Urea Cycle Disorders Consortium (UCDC) in 14 metabolic clinics (11 of them in the US) as part of its long-term follow-up study. To ensure that the information the investigators analyze is representative of the UCD patient population in the US, the investigators will also obtain data from the Studies of Pediatric Liver Transplantation (SPLIT) registry, which collects information about children who undergo liver transplantation for many different diseases (including UCD). The National Urea Cycle Disorders Foundation (NUCDF) and the Patients' Research Working Group collaborated with the clinical investigators to design this research and to ensure that it that it covers the questions that are most important to patients and their families. The results of this study will be disseminated to patients, their doctors, and clinical staff so they receive current, validated information before making a decision about the best treatment for them.


Recruitment information / eligibility

Status Completed
Enrollment 187
Est. completion date June 30, 2020
Est. primary completion date June 10, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 18 Years
Eligibility Inclusion Criteria: Aim 1 (UCD patients): - Age 18 and under - Diagnosed with the following Neonatal-type urea cycle disorders: - CPSD, OTCD, ASD or ALD, as defined as follows: - Diagnosis of CPS I deficiency, defined as decreased (less than 20 % of control) CPS I enzyme activity in liver, and/or an identified pathogenic mutation, and/or hyperammonemia and first-degree relative meets at least one of the criteria for CPS I deficiency - Diagnosis of OTC deficiency, defined as the identification of a pathogenic mutation, and/or less than 20% of control of OTC activity in the liver, and/or elevated urinary orotate (greater than 20 uM/mM) in a random urine sample or after allopurinol challenge test, and/or hyperammonemia and first degree relative meets at least one of the criteria for OTC deficiency - Diagnosis of AS deficiency (Citrullinemia), defined as a greater than or equal to 10-fold elevation of citrulline in plasma, and/or decreased (less than 20% of control) AS enzyme activity in cultured skin fibroblasts or other appropriate tissue, and/or identification of a pathogenic mutation in the AS gene, and/or hyperammonemia and first degree relative meets at least one of the criteria for AS Deficiency - Diagnosis of AL deficiency (Argininosuccinic Aciduria, ASA), defined as the presence of argininosuccinic acid in the blood or urine, and/or decreased (less than 20% of control) AL enzyme activity in cultured skin fibroblasts or other appropriate tissue, and/or identification of a pathogenic mutation in the AL gene, and/or hyperammonemia and first degree relative meets at least one of the criteria for AL Deficiency - Willing to participate in at least 1 neurocognitive assessment and 1 quality of life assessment - Permit access to medical records and medical providers Exclusion Criteria: Aim 1: - Rare and unrelated comorbidities (e.g., Down's syndrome, intraventricular hemorrhage in the newborn period, and extreme prematurity)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No Intervention Given


Locations

Country Name City State
United States Childrens Research Institute Washington District of Columbia

Sponsors (7)

Lead Sponsor Collaborator
Children's National Research Institute Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), George Washington University, National Center for Advancing Translational Science (NCATS), Patient-Centered Outcomes Research Institute, Studies of Pediatric Liver Transplantation, The National Urea Cycle Disorders Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mortality This aspect of Aim 1 is prospective by design based on selection by exposure (liver transplant or medical managed) evaluating the clinical outcomes of subjects with urea cycle disorders. 436 person years in the Liver Transplant Group and 386 person-years in the Without Transplant Group
Primary Neurocognitive Function: Full-Scale IQ Neuropsychological tests were based on age-matched norms for the specific test used. All neurocognitive scores have been standardized to the following: norm, mean of 100, and sd of 15. In all tests higher scores are interpreted as higher functions. The WPPSI and WASI were combined to create a single measure of Full-Scale IQ.
Full-Scale IQ
Wechsler Preschool and Primary Scales of Intelligence, 4th edition (WPPSI-IV: Children 3-5 years of age)
Wechsler Abbreviated Scales of Intelligence, 1st and 2nd editions (WASI-I & II: Persons 6+ years of age)
Neuropsychological testing was conducted once for each patient at baseline during the study on age-matched norms for the specific test used.
Primary Total Quality of Life Quality of life assessments are self-reported by participating patients or by their parent/caretaker using the following reports:
Pediatric Family Impact (PedsQL), Version 4 is reported as a total score
All were scored on a 0-100 scale. Higher scores indicated a better health-related quality of life
Quality of life testing was conducted and reported at baseline for each patient during the study.
See also
  Status Clinical Trial Phase
Completed NCT02252770 - Nitric Oxide Supplementation in Argininosuccinic Aciduria N/A
Completed NCT01002469 - Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment N/A
Completed NCT00986895 - A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group Phase 1
Completed NCT01257737 - To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs) Phase 4
Recruiting NCT05671666 - Ureagenesis Analysis in Healthy Subjects and in Urea Cycle Disorder Patients N/A
Completed NCT02489292 - Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002) Phase 2
Completed NCT02311283 - Pilot Study: Urea Cycle Disorders Practice Patterns and Outcomes Assessment N/A
Completed NCT00992459 - Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders Phase 3
Completed NCT00551200 - Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders Phase 2
Completed NCT00947297 - Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD) Phase 3
Completed NCT02051049 - Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)
Completed NCT01765283 - Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Phase 1/Phase 2
Completed NCT00947544 - Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders Phase 2
Completed NCT01347073 - Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs) Phase 3
Completed NCT00718627 - Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders Phase 2
Completed NCT03797131 - Clinical Food Study to Evaluate the Effect of KB195 on Gut Nitrogen Metabolism in Patients With Urea Cycle Disorders N/A
Completed NCT01549015 - Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function N/A
Terminated NCT01541722 - Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders N/A
Completed NCT00345605 - Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder Phase 2
Recruiting NCT00237315 - Longitudinal Study of Urea Cycle Disorders